share_log

Accuray Receives CE Mark for a New Helical Radiation Delivery System, Accuray Helix

Accuray Receives CE Mark for a New Helical Radiation Delivery System, Accuray Helix

Accuray爲新的螺旋放射傳遞系統Accuray Helix獲得CE標誌。
PR Newswire ·  08/27 07:35
  • Developed for India and other countries where patient access to care with radiotherapy is challenged and where versatility and ease of use are a high priority
  • Drives the next phase of company's strategic plan to expand its portfolio of helical radiation therapy delivery systems
  • 專爲印度和其他患者接受放射治療的國家開發,注重靈活性和易用性。
  • 推動公司戰略計劃的下一階段,擴大螺旋放射治療系統的產品組合。

MADISON, Wis., Aug. 27, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company has received CE Mark for Accuray Helix, a CT-guided helical radiotherapy system designed to provide high-performance and high-throughput. The new system is intended for emerging markets where access to advanced cancer care, including radiotherapy treatments, is typically obtainable only within urban areas and where the availability of linear accelerators per million population is well below the World Health Organization recommended guidelines. Accuray Helix offers a solution for clinical teams that require short treatment times and cost effectiveness to establish a care path for patients in non-urban communities who previously had limited options.

威斯康辛州麥迪遜,2024年8月27日/美通社/-- Accuray Incorporated(納斯達克:ARAY)今天宣佈,該公司已獲得Accuray Helix的CE標誌,這是一種CT引導的螺旋放射治療系統,旨在提供高性能和高通量。新系統適用於新興市場,其中只有在城市地區才能獲得先進癌症治療,包括放射治療,而每百萬人口的線性加速器可用性遠低於世界衛生組織推薦的指南。 Accuray Helix爲臨床團隊提供了一個解決方案,他們需要短時間的治療和具有成本效益的方法來爲非城市社區的患者建立護理路徑,而這些患者以前的選項有限。

Radiotherapy is a fundamental component of cancer care1 and can be used in the treatment of localized disease, recurrent or metastatic cancer. An estimated 50 percent of people with cancer would benefit from radiation therapy2 either as their sole care option or along with other modalities such as surgery, chemotherapy or immunotherapy.

放射治療是癌症治療的基本組成部分1,可用於治療局部疾病、複發性或轉移性癌症。估計有50%的癌症患者將受益於放射治療2,無論是作爲他們唯一的治療選擇還是與其他治療方式(如手術、化療或免疫療法)一起使用。

"While the demand for cancer services is increasing globally, there are certain areas of the world where there continues to be greater gaps in access to radiation medicine. India is a priority due to this disparity as there is a significant deficit in availability of radiation therapy systems compared to the size if its population and incidence of cancer. Our goal with the introduction of Accuray Helix is to close some of these gaps to patient access with our comprehensive solutions," said Suzanne Winter, president and CEO of Accuray. "The Accuray Helix system combines affordability with automation and tools for enhancing the speed of planning and delivery of radiation. We believe it will enable a broader range of capabilities for facilities that may have resources and staffing for only one system, enabling them to offer state-of-the-art cancer care in their communities."

「在全球範圍內,對癌症服務的需求正在增加,但世界某些地區在輻射醫學方面仍存在更大的差距。印度由於存在這種差距而成爲優先事項,因爲與其人口規模和癌症發病率相比,放射治療系統的可用性存在顯着缺口。我們通過引入Accuray Helix的目標是爲患者提供全面解決方案,以消除他們在接受治療方面的一些障礙,我們的綜合解決方案,」稱Accuray總裁兼首席執行官Suzanne Winter。「Accuray Helix系統將價格實惠與自動化和增強放射治療計劃和傳遞速度的工具相結合。我們相信這將使那些只有一套設備的設施能夠提供先進的癌症護理。」

Accuray Helix delivers precise, targeted radiation treatments, an important option for the routine cases clinical teams see daily in their practice including breast, cervix, head and neck, gastrointestinal, lung and prostate. The system's flexibility and versatility are intended to drive improvements in personalization and patient care, while simultaneously facilitating treatment of more patients each day, boosting productivity for clinics and enabling them to efficiently manage the growing demand for cancer care.

Accuray Helix提供精確、靶向的放射治療,對於臨床團隊每天在常規病例中看到的包括乳腺、宮頸、頭頸部、胃腸、肺部和前列腺在內的疾病治療來說,這是一個重要的選擇。該系統的靈活性和多功能性旨在推動個性化治療和患者護理的改善,同時提高每天的患者數量,提高診所的生產力,並使其能夠高效管理對癌症護理日益增長的需求。

Important Safety Information
For Important Safety Information please refer to .

重要安全信息
有關重要的安全信息,請參見。

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit or follow us on Facebook, LinkedIn, X, and YouTube.

關於Accuray公司
Accuray致力於擴大輻射治療的強大潛力,以儘可能地改善生活。我們發明了獨特的、市場領先的解決方案,旨在爲即使是最複雜的病例提供輻射治療 - 同時使常見的病例治療變得更加容易 - 以滿足患者需求的全譜。我們致力於在放射治療、神經放射外科等方面的不斷創新,與臨床醫生和管理人員合作,賦予他們幫助患者更快地回到生活的能力。Accuray總部位於威斯康星州麥迪遜市,並在全球設有設施。欲了解更多信息,請訪問或在Facebook、LinkedIn、X和YouTube上關注我們。

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to expectations related to Accuray Helix and its effect on the field of radiation oncology and clinical practice, expectations with respect to the markets in the company plans to offer Accuray Helix, clinical applications, clinical results, patient experiences and patient outcomes These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product innovations and releases; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on May 8, 2024, and as updated periodically with the company's other filings with the SEC.

Safe Harbor聲明
本新聞稿中的聲明不屬於歷史事實,屬於前瞻性聲明,並受1995年《私營證券訴訟改革法》安全港規定的保護。本新聞稿中的前瞻性聲明涉及但不限於與Accuray Helix及其對放射腫瘤學和臨床實踐領域的影響有關的預期、公司計劃提供Accuray Helix的市場預期、臨床應用、臨床結果、患者體驗和患者結果。這些前瞻性聲明涉及風險和不確定性。如果這些風險或不確定性中的任何一項實現,或者公司的任何假設被證明不正確,實際結果可能與這些前瞻性聲明所表達或暗示的結果有實質性的差異。這些風險和不確定性包括但不限於公司能否廣泛市場接受其產品,包括新產品創新和發佈;公司能否開發新產品或改進現有產品以滿足客戶需求;公司能否預見或跟上市場變化、技術創新和客戶需求的方向,並根據SEC於2024年5月8日提交的公司季度報告第10-Q中「風險因素」標題所指明的風險以及定期更新的公司與SEC的其他提交文件。

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

前瞻性陳述僅適用於發表陳述的日期,並且是基於公司在那些聲明發表時可用的信息和/或管理層對未來事件的信心以及當時的良好信仰。公司假定沒有義務更新前瞻性陳述以反映實際表現或結果,也沒有義務更新前瞻性信息的假設或影響前瞻性信息的其他因素,除非適用的證券法律要求。因此,投資者不應過度依賴任何前瞻性陳述。

Media Contact
Beth Kaplan
Accuray
+1 (408) 789-4426
[email protected]

媒體聯繫人
Beth Kaplan
精確射線
+1(408)789-4426
[email protected]

1INTERNATIONAL ATOMIC ENERGY AGENCY, Radiotherapy in Cancer Care: Facing the Global Challenge, Non-serial Publications , IAEA, Vienna (2017).
2Atun et al. Expanding global access to radiotherapy. Lancet Oncol 2015; 16:1153-86.

國際原子能機構,《面對全球挑戰的癌症放射治療》,非連續出版物,維也納(2017年)。
Atun等人。擴大全球範圍內的放射治療接入。《柳葉刀腫瘤學雜誌》2015年;16:1153-86。

SOURCE Accuray Incorporated

來源:精確射線公司

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論